Nuveen California Select Tax-Free Income Portfolio
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- Sector
- Financial Services
- Industry
- Asset Management - Income
- Address
- 333 West Wacker Drive Chicago IL United States of America 60606-1220
- IPO Date
- Jun 19, 1992
- CIK
- 0000885732
- Website
- nuveen.com
- Similar Companies
- Business
- Nuveen California Select Tax-Free Income Portfolio (Ticker: NXC) is a closed-end fund primarily engaged in providing stable, tax-exempt income by investing in a diversified portfolio of municipal securities. The fund focuses on investment-grade municipal bonds with up to 20% of assets allocated to lower-rated securities, including a portion rated below B-/B3. It employs strategies such as inverse floating rate municipal securities and tender option bonds, creating effective leverage to enhance income. Nuveen manages the fund with an emphasis on preserving capital while delivering dividends exempt from federal and California state income taxes. Founded as part of Nuveen's suite of municipal bond products, the fund primarily serves income-focused investors in California seeking tax-advantaged investment solutions. Recent strategic developments at Nuveen include the acquisition of Brooklyn Investment Group, a leading multi-asset custom direct indexing provider, which expands Nuveen's capabilities in personalized, tax-managed investment solutions integrating active tax management with private market alternatives and lifetime income products. Nuveen also announced a strategic partnership with Hunter Point Capital and Temasek, targeting the private capital markets with a focus on sectors such as clean energy, healthcare, and industrial real estate through long-term, ESG-aligned investments. Additionally, Nuveen real estate operations made a significant €538 million acquisition in the French student housing sector, diversifying its geographic footprint in real assets. The firm has deepened its technological collaboration with Cherre, a real estate data platform, enhancing data management and operational efficiencies across its global portfolios. Nuveen, headquartered in Chicago, Illinois, operates across the U.S. and Europe, managing a broad array of investment products including municipal bonds, real estate, private equity, and direct indexing solutions. With assets under management exceeding $1.3 trillion, Nuveen delivers investment advisory, asset management, and strategic partnership services to institutional, retail, and wealth management clients. The California Select Tax-Free Income Portfolio exemplifies Nuveen's focus on tax-efficient municipal fixed income products tailored to meet regional tax considerations, supported by the firm's advanced portfolio management and risk infrastructure. The fund continues to provide consistent dividend distributions and targets preservation of capital and tax-advantaged income generation for its shareholders. Recent innovations in product offerings and strategic alliances reflect Nuveen's commitment to expanding its capabilities in personalized asset management and sustainable investing.
Company News
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
Nuveen Select Tax-Free Income Portfolios Announce Completion of Reorganizations
Nuveen Closed-End Funds Announce Update to Reorganization Distributions
Nuveen Select Tax-Free Income Portfolios Announce Shareholder Approval of Reorganization
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
Nuveen Wants To Merge NXC And NXN Into NXP: What Now?
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025
Sell Equities, Buy Municipal Debt At A 7.21% Discount With Nuveen California Select Tax-Free Income Portfolio
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
Nuveen Closed-End Funds Declare Distributions and Updates to Distribution Policies
Weekly Closed-End Fund Roundup: January 8, 2023
Weekly Closed-End Fund Roundup: VFL Tender Results (December 18, 2022)
Weekly Closed-End Fund Roundup: June 21, 2020
The Reopening Killed The V-Shaped Recovery